advertisment
Supported by
As the United States withdraws from global affairs, Russia promises other nations to oppose the pandemic.
By Judyth Twigg
Dr. Twigg is a professor of political science.
Before regulators took office this month, there was a clever explanation for why he was involved in President Trump’s sudden increase in a coronavirus vaccine, but he had no longer become the first world leader to get approval. Vladimir Putin of Russia had already done so. And unlike Trump’s “America First” technique, Putin is using his unproven vaccine in a world press on the right to make friends and his country’s comfortable power.
On 11 August, the Russian Ministry of Health officially approved the Sputnik V vaccine, developed through the Gamaleya Institute for Epidemiology and Microbiology Research in Moscow. His announcement was a brilliant event. A seven-language online page featured a recording of beeps broadcast from the area in 1957 confirming that the first Soviet Sputnik satellite was in orbit. These ancient echoes ostensibly evoked the concept that Russia supported number one.
But at this stage, the vaccine had not even begun large-scale cash trials, which neither its protection nor its effectiveness had been fully verified and knowledge of its early-stage clinical trials had not been published. Since then, a peer-reviewed publication of The First Promising Effects in The Lancet magazine has sounded the alarm for some scientists who are involved about possible inconsistencies in knowledge, something a high-level Russian scientist has denied.
Still, smart vaccine news saturates Russian state-controlled media, and the country is in a position to take advantage of Sputnik for a primary diplomatic coup. This is another example, in addition to the U. S. withdrawal from Syria, its departure from the Paris weather agreement, and its planned withdrawal from the World Health Organization, where the us exit globally created a vacuum that Mr. Putin created. You’ve been very happy to complete.
Because vaccines are given to healthy people, they face mainly major regulatory barriers. Complete phase three trials, designed to encounter rare side effects and verify efficacy among diverse populations, involve thousands or tens of thousands of people. The Sputnik vaccine trial consisted of only 76 people.
Lately, the Moscow mayor’s office is home to up to 40,000 volunteers for end-stage testing while providing the vaccine to frontline doctors and teachers. Skipping the weapon has potentially fatal consequences, adding a new spread of the virus if a weakly effective vaccine activates others. be happy with masking and physical distance before collective immunity is established.
In the United States, vaccines that are likely to be applicants for emergency use authorizations from the Food and Drug Administration are at least partially the subject of phase 3 testing.
Of course, Sputnik can paint very well. Russia has many world-class scientists and the Gamaleya Institute says it has gone one step ahead. The institute highlights the progression of an Ebola vaccine and says Sputnik is just a slightly modified edition of its Middle East respiratory syndrome vaccine. evidence that these vaccines have been implemented particularly around the world.
Now, countries’ rush to get a possible coronavirus vaccine closely resembles a repeat of what happened in the 1990s with antiretrovirals to fight HIV/AIDS and in 2009 with the H1N1 flu vaccine: nations buy the initial supply, probably peaking leaving only the remnants for the rest of the world much later, if any.
The United States, for example, has received early procurement commitments of more than 800 million doses of at least six candidate vaccines, all for themselves. Adding a symbol of selfishness, Trump’s management demonstrated last month that he would not enroll in Covax. effort across dozens of countries to make some massive source and equitable distribution of vaccines. This resolution created a political area for Russia to tame the role of benefactor, nor did it sign up for Covax’s effort.
Russia is launching production licenses and donations in dozens of countries for Sputnik. These agreements are not limited to apparent friends and neighbors such as Belarus and Kazakhstan. Pending regulatory approval, India is expected to produce at least three hundred million doses and acquire one hundred million. more doses; The Brazilian state of Bahia will buy 50 million and Mexico has an acquisition agreement of 32 million.
In total, Russia requests initial applications from at least 40 partners for a total of more than one billion doses.
We do not yet know the terms of these agreements, and the “pending regulatory approval” clause is important; Agreements may fail if Sputnik’s security and effectiveness do not materialize, Russia is trying to allay those fears by assuming some of the legal duty for adverse events. If you lead Mexico, the Philippines or Brazil, shaken by months of medical, social and economic impact problems, you may be willing to try your luck with a Russian product that has not been fully tested and probably relatively reasonable and that you may have in your hands soon, especially if it turns out that the United States and Europe are letting it go alone.
Putin’s only rival to the role of global savior is China, which is also taking regulatory action for vaccines and pushing for agreements, such as a $1 billion loan for Latin American and Caribbean countries to pay for them.
Although the Kremlin is committed to a pandemic-related belt adjustment like everyone else, it has little debt and $120 billion in liquid assets in its sovereign fund, possibly allowing for safe vaccine generosity. The symbol would be the value of the price.
Sputnik is also the fodder of a disinformation crusade that has already spread in Russian state-controlled media. The claim is that only the Russian vaccine is effective.
Russia has a long history, dating back to Soviet times, of health-related misinformation. The KGB spread “fake news” worldwide in the early 1980s, claiming that the HIV/AIDS virus is an American biological weapon. Trolls and robots have been actively trying to erode public confidence in vaccines in the United States since at least 2014.
For Russia, the Sputnik vaccine goes far beyond national pride. Putin wants a surprising victory after a lot of recent bad press. He uses his popular playbook, taking advantage of the merits of a weak hand and exploiting America’s mistakes and vulnerabilities. unilateralism, forgetfulness or abandonment of key allies, withdrawal from established science, the symbol of Russia and its global position as a wonderful power.
Russia is betting that its short-term diplomatic achievements will overcome the threat to long-term reputation in the face of a challenge with the Sputnik vaccine. The United States can simply counter Russia’s bet and make a contribution to a significant smart global audience through modest investment in Covax’s vaccination effort.
Do we need to give the floor to Mr Putin?
Judyth Twigg is a professor of political science at Virginia Commonwealth University, specializing in global fitness with a major in Russia and Eurasia.
The Times is committed to publishing one of the letters to the publisher. We would like to know what you think of this article or one of our articles. Here are some tips. And here’s our email: lettres@nytimes. com.
Follow the New York Times Review segment on Facebook, Twitter (@NYTopinion) and Instagram.
advertisment